ATG2A: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of ATG2A. The page also collects GeneMedi's different modalities and formats products for ATG2A in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the ATG2A target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Secreted Protein/Potential Cytokines.
Predicted to enable phosphatidylinositol-3-phosphate binding activity. Involved in autophagosome assembly. Predicted to be located in endoplasmic reticulum membrane; lipid droplet; and phagophore assembly site membrane. Predicted to be active in phagophore assembly site. Predicted to be extrinsic component of membrane. [provided by Alliance of Genome Resources, Apr 2022]
|Gene Symbol and Synonyms||1810013C15Rik,A830054M12,ATG2A,BLTP4A,mKIAA0404|
|Uniprot Entry Name||ATG2A_HUMAN|
|Protein Sub-location||Secreted Protein/Potential Cytokines|
Pre-made anti-ATG2A inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-ATG2A benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-ATG2A mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
|Antibody Name||Species||Format||Classified by tag||Detail|
|Anti-ATG2A monoclonal antibody||Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine||mab||FACS/Biofunctional Antibody||Detail|
Recombinant multi-species ATG2A protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine ATG2A protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
|Products Name||Species||Expression Platform||Detail|
|ATG2A protein||Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine||Mammalian cell||Detail|